Show simple item record

FieldValueLanguage
dc.contributor.authorMullany, Kathryn Louise
dc.date.accessioned2025-09-01T06:32:24Z
dc.date.available2025-09-01T06:32:24Z
dc.date.issued2025en
dc.identifier.urihttps://hdl.handle.net/2123/34263
dc.description.abstractAdvancements in genetic therapies, including recombinant adeno-associated virus (AAV) technologies, have now reached a point where potential curative treatments are within reach for incurable genetic diseases such as Maple Syrup Urine Disease (MSUD). MSUD is caused by biallelic mutations in one of five autosomal genes required for the enzyme BCKDH. Current treatment options are non-curative. This thesis explored the potential of recombinant AAV technology as a novel therapy for MSUD using a DBT-deficient neonatal lethal murine model. This thesis first explored a liver directed approach with AAV8 pseudoserotyped vectors carrying a human DBT transgene under the transcriptional regulation of the APOe/hAAT enhancer/promoter. These experiments used conventional and hybrid AAV/piggyBac transposase vectors and found that both integrating and non-integrating AAV vectors significantly improved the physical and biochemical phenotype of DBT-deficient mice, though the rescue was only transient with non-integrating vectors. A muscle restricted vector was also developed and included the CK8e promoter/enhancer, a human DBT transgene and was packaged in the muscle trophic AAVMYO capsid. MicroRNA targeting site sequences were also included to de-target transgene expression in the liver and brain. Neonatal injection of the muscle optimised vector successfully rescued DBT-deficient mice to adulthood with biophysical parameters statistically equivalent to those observed in wildtype mice during periods of metabolic stability and transgene expression was highly muscle restricted. Whilst further, rigorous pre-clinical testing is required before an equivalent muscle optimised vector would be safe for human clinical application, this thesis has demonstrated the viability of AAV-mediated gene transfer to skeletal muscle, a post mitotic tissue, in a neonatal lethal MSUD murine model and is an encouraging step in the search for a cure for MSUD patients and their familiesen
dc.language.isoenen
dc.subjectAdeno-associated virusen
dc.subjectmaple syrup urine diseaseen
dc.subjectGene therapyen
dc.subjectDBT geneen
dc.subjectliveren
dc.subjectskeletal muscleen
dc.titleAdeno-Associated Virus Gene Therapy For Maple Syrup Urine Diseaseen
dc.typeThesis
dc.type.thesisDoctor of Philosophyen
dc.rights.otherThe author retains copyright of this thesis. It may only be used for the purposes of research and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission.en
usyd.facultySeS faculties schools::Faculty of Medicine and Healthen
usyd.departmentChildren's Medical Research Instituteen
usyd.degreeDoctor of Philosophy Ph.D.en
usyd.awardinginstUniversity of Sydneyen
usyd.advisorAlexander, Ian
usyd.include.pubNoen


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.